Aakaar Medical Technologies Limited
Aakaar Medical Technologies Limited, established in June 2013, specializes in aesthetic medical products and devices, serving dermatologists, plastic surgeons, and aesthetic physicians in India through a B2B model.
What Aakaar files
- Others20
- Investor Meet19
- Updates10
- Important7
- Board Meeting5
- PPTs2
Aakaar Medical's Q1 FY27 shows strong operational progress, with Xelix clinic network targeting 100 by H2 end. FY27 revenue growth guided ~30%, EBITDA ~25%. Strengthening distribution and sales force initiatives are underway to enhance market reach and financial efficiency.
Aakaar Medical Technologies reported strong H2 & FY26 financial results. H2 revenue reached 41.6 Cr and PAT 7.4 Cr, rebounding from H1 losses. The company launched four new high-growth brands and unveiled XELIX, a doctor-owned aesthetics platform leveraging its 6300+ doctor network.
Aakaar Medical Technologies' Board has updated its Code for Fair Disclosure of Unpublished Price Sensitive Information. This strengthens rules for handling and releasing market-sensitive data, aiming for transparency and preventing selective disclosure.
Aakaar Medical Technologies' promoters confirmed no encumbrance (pledging) on their equity shares for the financial year ended March 31, 2026. This indicates stability and signals strong promoter commitment.
Aakaar Medical has partnered with Tricopat, adding a patented non-invasive hair & scalp treatment system to its portfolio. This strategic tie-up strengthens Aakaar's offerings, aiming for increased clinic utilization and recurring procedure revenue.